首页> 外文OA文献 >Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

【2h】

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

机译：I期剂量 - 升级试验调查Volasertib作为单疗法或与复发/难治性急性髓性白血病患者的患者组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Oliver G. Ottmann; Carsten Müller-Tidow; Alwin Krämer; Richard F. Schlenk; Michael Lübbert; Gesine Bug; Utz Krug; Tilmann Bochtler; Florian Voss; Tillmann Taube; Dan Liu; Pilar Garin-Chesa; Hartmut Döhner;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia [J] . Ottmann Oliver G., Müller‐Tidow Carsten, Kr?mer Alwin, British Journal of Haematology . 2019,第6期

机译：I期剂量 - 升级试验调查Volasertib作为单疗法或与复发/难治性急性髓性白血病患者的患者组合
2. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study [J] . The lancet oncology . 2020,第4期

机译：威尼柯克克斯与在复发或难治性急性髓性白血病的儿童中或没有含替代的含有缺陷的含糖蛋白：1期，剂量升级研究
3. A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficay of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy [J] . Donnellan William B., Atallah Ehab L., Asch Adam S., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：I / II阶段，开放标签，多期形二份研究，评估AZD2811纳米粒子的安全性，耐受性，药代动力学和效率作为单一疗法或组合在治疗 - 幼稚或复发/难治性急性髓性白血病/髓细胞增强综合征患者有资格获得密集的诱导治疗
4. Design of optimal disease and patient-specific chemotherapy protocols for the treatment of Acute Myeloid Leukaemia (AML) [C] . E. Pefani, N. Panoskaltsis, A. Mantalaris International Symposium on Process Systems Engineering . 2012

机译：用于治疗急性髓性白血病（AML）的最佳疾病和患者特异性化疗方案的设计
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised controlled double-blind multinational phase 3 study [O] . Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, -1

机译：首次复发或难治性急性髓细胞性白血病（VALOR）患者中的Vosaroxin加阿糖胞苷与安慰剂加阿糖胞苷的比较：一项随机对照双盲多国3期研究
7. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation [O] . Jackson G, Taylor P, Smith G M, 2001

机译：一项多中心，开放，非对照II期研究，氟达拉滨磷酸，阿糖胞苷和粒细胞集落刺激因子联合治疗复发性和难治性急性髓细胞性白血病和新生难治性贫血并伴有大量母细胞转化

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

著录项

引文网络

相似文献

相关主题

期刊订阅